Ignite Creation Date:
2024-05-06 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 2:21 PM
Study NCT ID:
NCT05169801
Status:
COMPLETED
Last Update Posted:
2021-12-27
First Post:
2021-12-23
Brief Title:
To Compare the Efficacy and Safety of BP102 vs Avastin in Combination With PaclitaxelCarboplatin in First-line Treatment of Advanced or Relapsed NSCLC
Sponsor:
Jiangsu HengRui Medicine Co Ltd
Organization:
Jiangsu HengRui Medicine Co Ltd
Study Overview
Official Title:
To Compare the Efficacy and Safety of BP102 in Combination With PaclitaxelCarboplatin and Avastin in Combination With PaclitaxelCarboplatin in First-line Treatment of Advanced or Relapsed NSCLC - a Randomized Double-blind Positive Parallel Control Multicentre Phase III Clinical Trial
Status:
COMPLETED
Status Verified Date:
2021-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized double-blind positive parallel control multicentre Phase III clinical trial a clinical trial of biosimilar drugs so the type of comparison is equivalence test
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None